Vaxcyte, Inc. - 8-K Filing
Vaxcyte reports positive topline data from Phase 3 OPUS-1 trial for its 31-valent pneumococcal conjugate vaccine candidate, meeting all primary endpoints. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $PCVX